Ruxolitinib inhibits poly(I:C) and type 2 cytokines-induced CCL5 production in bronchial epithelial cells: A potential therapeutic agent for severe eosinophilic asthma.

Mitsuru Sada Masato WatanabeToshiya InuiKeitaro NakamotoAya HirataMasuo NakamuraKojiro HondaTakeshi SarayaDaisuke KuraiHirokazu KimuraHaruyuki Ishii Hajime Takizawa

Published in: Immunity, inflammation and disease (2021)

We have demonstrated that JAK1 is a possible therapeutic target for severe corticosteroid-resistant asthma with airway eosinophilia and persistent Th2-type inflammation, and that ruxolitinib has potential as an alternative pharmacotherapy.

Keyphrases

chronic obstructive pulmonary disease
drug induced
lung function
liver injury
early onset
oxidative stress
allergic rhinitis
diabetic rats
high glucose
smoking cessation
cystic fibrosis
human health
liver fibrosis
risk assessment